Hospitals Segment to Dominate SAM Lymphedema Treatment Market during 2021–2028

According to a new market research study on “SAM Lymphedema Treatment Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Condition Type, Treatment Type and End-User” is expected to reach US$ 419.04 million by 2028 from US$ 300.85 million in 2021. The market is estimated to grow at a CAGR of 4.8% from 2021 to 2028. The report provides trends prevailing in the SAM lymphedema treatment market along with the drivers and restraints pertaining to the market growth. Rising incidence of lymphedema cases is the major factor driving the growth of the SAM lymphedema treatment market. However, issues associated with the lack of awareness and skilled professionals hinder the growth of SAM lymphedema treatment market.  

The SAM lymphedema treatment market is segmented into condition type, treatment type, end-user and country. Based on type, the SAM lymphedema treatment market is segmented into primary lymphedema and secondary lymphedema. The secondary lymphedema segment dominated the market in 2020 and primary lymphedema is expected to be the fastest growing during the forecast period. Based on treatment type, the SAM lymphedema treatment market is segmented into laser therapy, compression devices and bandaging, drug therapy, physiological procedures, debulking procedures, and others. The compression devices and bandaging segment dominated the market in 2020 and debulking procedures segment is expected to be the fastest growing during the forecast period. Further physiological procedures segment is bifurcated into lymphovenous anastomosis (LVA) and vascularised lymph node transfer (VLNT).Based on end-user, the SAM lymphedema treatment market is segmented into hospitals, clinics, clinical research organizations, and others. The hospitals segment dominated the market in 2020 and clinics is expected to be the fastest growing during the forecast period. Based on country, SAM lymphedema treatment market is classified into Brazil, Argentina, and Rest of SAM.

The pandemic situation has subsequently resulted in the delay in spreading adequate awareness programs in the SAM region.  The current global coronavirus disease 2019 (COVID-19) pandemic has not only resulted in millions of deaths but also posed indirect effects on other diseases and healthcare programs. In view of the current COVID-19 pandemic, and the need to maintain social distancing, government organizations issued the recommendation on 1st April 2020 to put all community-based surveys, active case-finding activities, and mass treatment campaigns for neglected tropical diseases on hold until further notice. However, as the cases of lymphedema treatment were rising in the region, government bodies bought the concept of telemedicine through which the awareness programs could reach the people suffering from lymphedema in Brazil and Argentina and help them in mitigating such risks. Another factor is that there are no proper treatments or cures for the concerned disease. The developing economies face risks as they could not address such risk factors posing threat to mankind. However, healthcare investments in Brazil and proper regulations are expected to positively impact the lymphedema treatment market in both Brazil and Argentina.

3M Company, BSN medical GmbH, Huntleigh Healthcare Limited, Lohmann & Rauscher GmbH & Co. KG, Mego Afek ltd, Sigvaris Group, and Smith & Nephew are among the leading companies in the SAM lymphedema treatment market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in 2021, Mego Afek ltd. has announced preliminary data for Lympha Press PCD-51 to be used in chronic venous stasis ulcers.

SAM Lymphedema Treatment Market, By Country, 2020 and 2028 (%)

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com